No Picture
News

Shenogen enters into an Exclusive License with BioArdis to Develop and Commercialize Novel FGFR4 Kinase Inhibitor for Asian Market

BEIJING and SHANGHAI and SAN DIEGO, April 3, 2020 /PRNewswire/ — Shenogen, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in China … […]

No Picture
News

Shenogen enters into an Exclusive License with BioArdis to Develop and Commercialize Novel FGFR4 Kinase Inhibitor for Asian Market

BEIJING and SHANGHAI and SAN DIEGO, April 3, 2020 /PRNewswire/ — Shenogen, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in China … […]

No Picture
News

SORRENTO TO PROVIDE MANUFACTURING SUPPORT TO CELULARITY AS CYNK-001 NK CELL TRIAL FOR COVID-19 BEGINS ENROLLING PATIENTS

SAN DIEGO, April 02, 2020 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced it has initiated the next phase of its collaboration with Celularity, Inc., a Warren, New Jersey, based clinical-stage cell therapeutics co… […]

No Picture
News

Persephone Biosciences Announces AI-Driven Microbiome Therapeutic and Diagnostic Programs for COVID-19

Treatment approach goes beyond combating COVID-19 and may be effective against mutations, seasonal flu and future pandemics

SAN DIEGO, April 2, 2020 /PRNewswire/ — Persephone Biosciences Inc., a biotechnology company that designs microbiome therape… […]

No Picture
News

Ansun Biopharma Announces Positive Results from Investigator-Initiated Trial of Novel COVID-19 Treatment

Treatment with DAS181, a clinical-stage recombinant biologic, reduced or eliminated the need for supplemental oxygen, and improved key patient vital signs

SAN DIEGO, April 2, 2020 /PRNewswire/ — Ansun Biopharma, Inc., a clinical stage biopharmaceuti… […]